Meet The Team
Dori Thomas-Karyat, PhD
Founder and CEO
Dori has 20+ years of experience in the immuno-oncology space. She is an expert in the field of TGF-ß. Prior to founding Synthis Therapeutics, Dori worked in pharma drug discovery at Abbvie and Roche as a project lead. She did her Post-doctoral Cancer Research Institute fellow at MSKCC. She received her immunology Ph.D. from Washington University in St. Louis.
Viviana Volta, PhD
Viviana has 15+ years of multifaceted expertise in cancer, immunology, cell signaling and gene expression (translation), and extensive formal training in drug development and bio-entrepreneurship. Prior to Synthis, she was a post-doctoral fellow at NYU working on the combined role of protein synthesis control and TGFbeta on human regulatory T cell differentiation.
Bob Lutz, PhD
Dr. Lutz has 30+ years of biotech experience and is an expert in ADC discovery through clinical development. He is a scientific advisor for Synthis’ Immuno-oncology based ADC platform since 2016. Previously he worked at Immunogen as the Vice President of Translational Research and Development. He has research in Kadcyla, the first FDA-approved ADC for solid tumor indication and coltuximab ravtansine, a CD19 targeting ADC for DLBCL. Dr. Lutz received his BS and PhD in biochemistry from the University of New Hampshire and Brandeis University, respectively, and was a postdoctoral fellow at the Eleanor Roosevelt Institute.